November 2026 Br J Cardiol 2026;33(4) doi :10.5837/bjc.2026.054 Online First
James Hickson, Wen Hui Teh, Uditha Hewarathna, Mark Hayes
We present a case of carcinoid heart disease as a consequence of a metastatic neuroendocrine tumour. The importance of recognising carcinoid syndrome as a cause of tricuspid and pulmonary valve pathology, as well as potential treatment, are discussed.
November 2026 Br J Cardiol 2026;33(4) doi :10.5837/bjc.2026.055 Online First
Aditya Mukherjee, Andrew Ladwiniec, Gerry P McCann, Amitha Puranik, Coral Pepper, Thomas A Kite
Although international guidelines for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) have recently been updated, uncertainty remains about the optimal timing of an invasive strategy (IS). Further randomised trial data comparing such strategies have been published and merit inclusion in an updated analysis. We conducted a systematic review and meta-analysis to consolidate the current evidence-base.
A systematic review of randomised-controlled trials (RCTs) comparing early versus delayed IS was performed by searching MEDLINE, Embase and the Cochrane Central Register for Clinical Trials. Meta-analysis was performed by pooling the relative risks using a random-effects model. The primary outcome was all-cause mortality, while secondary end points included myocardial infarction (MI), recurrent ischaemia, admission for heart failure (HF), repeat revascularisation, major bleeding and stroke. The study was registered with the International Prospective Register of Systematic Reviews (PROSPERO ID: CRD42024578335).
Data from 18 RCTs were included in the analysis. There was no statistically significant difference in all-cause mortality (relative risk [RR] 0.89, 95% confidence interval [CI] 0.77 to 1.03), MI (RR 0.86, 95%CI 0.65 to 1.15), repeat revascularisation (RR 1.05, 95%CI 0.89 to 1.22), major bleeding (RR 0.89, 95%CI 0.70 to 1.12) or stroke (RR 0.93, 95%CI 0.58 to 1.48) between the groups. However, early IS was associated with a reduction in recurrent ischaemia (RR 0.54, 95%CI 0.38 to 0.78) and admission for HF (RR 0.76, 95%CI 0.60 to 0.95).
In conclusion, in patients admitted with NSTE-ACS, early IS was not associated with a reduction in all-cause mortality, repeat revascularisation, MI, major bleeding or stroke. Early IS reduced the risk of recurrent ischaemia and admission for HF.
November 2026 Br J Cardiol 2026;33(4) doi :10.5837/bjc.2026.056 Online First
Miriam Pikkemaat, Ulrika Andersson, Peter M Nilsson
Hypertension is the leading modifiable cardiovascular risk factor worldwide.1 Effective and inexpensive treatments are available, yet blood pressure control remains suboptimal in many countries.2 In Sweden, as in many other healthcare systems, hypertension management is largely delivered through primary care. This creates a major challenge, as the increasing number of patients with hypertension places additional pressure on a primary care already strained by workforce shortages and the growing healthcare needs of an ageing population.
November 2026 Br J Cardiol 2026;33(4) doi :10.5837/bjc.2026.057 Online First
Fatma Badr, Sheref Zaghloul
Coronary artery anomalies (CAAs) are typically discovered by accident during imaging. We describe a 57-year-old man who presented with chest pain suggestive of acute coronary syndrome. Invasive angiography revealed unobstructed coronaries with an anomalous left anterior descending (LAD) artery originating from the right coronary sinus. Computed tomography coronary angiography confirmed its anomalous nature and revealed a trans-septal (intramuscular) course between the aortic root and right ventricular outflow tract. This configuration is regarded as benign, unlike inter-arterial forms associated with ischaemia or sudden cardiac death. The patient remained asymptomatic on follow up. This case highlights the value of multimodal imaging in accurately assessing coronary anatomy, avoiding misdiagnosis and directing the appropriate course of treatment.
October 2026 Br J Cardiol 2026;33(4) doi :10.5837/bjc.2026.052 Online First
Mazhar Warraich, Ahmed Haggag, Dawar Ayyaz, Nadia Sunni
There is growing evidence for mortality with increasing age and comorbidities in implantable cardiac defibrillator receivers. We aimed to characterise how frailty and comorbidities impact mortality in patients receiving simple bradyarrhythmia device implants.
A retrospective cohort of 700 consecutive individuals who underwent novel bradyarrhythmia devices in a single centre were studied. Results were analysed using a multi-variate Cox regression model hazard ratios (HR) and Kaplan-Meier curves.
Mean implant age was 78.4 ± 10.3 years; 53.9% inpatient implants. All-cause mortality rate was 12.4% at one year. Mild-to-severe frailty measured by Rockwood frailty score (RFS) 5–9 was associated with mortality overall (HR 1.70, 95% confidence interval [CI] 1.30 to 2.21). Both inpatient (HR 1.57, 95%CI 1.19 to 2.08) and single-lead implants (HR 1.63, 95%CI 1.20 to 2.21) were associated with mortality.
Patient characteristics include male gender (HR 1.49, 95%CI 1.15 to 1.92) and age per 10-year increment (HR 1.75, 95%CI 1.46 to 2.09), heart failure syndrome (HR 1.52, 95%CI 1.13 to 2.05), valvular heart disease (HR 1.88, 95%CI 1.33 to 2.65), obesity (HR 2.97, 95%CI 1.42 to 6.21), chronic kidney disease (HR 1.34, 95%CI 1.00 to 1.79) and malignancy (HR 1.55, 95%CI 1.09 to 2.19) were associated with mortality.
In conclusion, higher RFS, male gender, heart failure syndrome, valvular heart disease, chronic kidney disease, obesity and malignancy were associated with mortality. Although advanced age does not preclude pacing, consideration should be given to frailty, which may detract from any perceived benefit bradyarrhythmia correction may offer.
September 2026 Br J Cardiol 2026;33:95–101 doi :10.5837/bjc.2026.041
Rosie Oatham, Kiana Mostaghimi, Lydia Bevis, Milos Prica, David Warriner
The population of adults living with congenital heart disease (CHD) has expanded substantially over the last 40 years due to advances in diagnostic, transcatheter, and surgical techniques. Consequently, clinicians, regardless of their specialty, will encounter patients presenting with sequelae of both simple and complex CHD more frequently. Familiarisation with the pathophysiology and basic management of these conditions, including the role of adult congenital heart disease (ACHD) centres, is, therefore, vital. The moderately complex congenital heart defects that may present in adulthood include atrioventricular septal defects (AVSD), Ebstein’s anomaly (EA), tetralogy of Fallot (TOF) and transposition of the great arteries (TGA). Some of these defects are typically diagnosed and repaired in infancy, so clinicians must be aware of the possibility of adults presenting with post-repair complications, but some patients with unrepaired or undiagnosed defects remain asymptomatic until middle age, where they may present with heart failure, arrhythmia, endocarditis or even sudden cardiac death.
September 2026 Br J Cardiol 2026;33:102–7 doi :10.5837/bjc.2026.042
Ravi Chotalia, Yasir Bakhit, Minesh Chotalia, Shirley Sze
Iron deficiency (ID) is common in patients with heart failure (HF) and is independently associated with poor outcomes, such as reduced functional capacity and quality of life, increased frailty and increased risk of HF hospitalisations and mortality. Intravenous iron has been shown to be an effective and well-tolerated therapy in patients with HF with reduced and mildly reduced ejection fraction and ID, improving quality of life and functional status and reducing the risk of HF hospitalisations. This review aims to summarise the evidence behind intravenous iron therapy in HF from recent key randomised-controlled trials. This review will also discuss the evidence for intravenous iron therapy in patients with HF with preserved ejection fraction. Ultimately, we also aim to review remaining uncertainties, such as sex-specific differences in outcomes, the optimal iron repletion and maintenance strategies, and the most accurate measures of ID in HF.
September 2026 Br J Cardiol 2026;33:115–8 doi :10.5837/bjc.2026.043
Brian Cunneen, Daniel O’Callaghan, Carmel O’Callaghan, Francis O’Neill, Bryan Loo, Peter Wheen, David Moore, David Mulcahy, Richard Armstrong, Vincent Maher
Coronary artery disease (CAD) remains a leading cause of morbidity and mortality globally, with early identification and management of risk factors being crucial to its management. Patients undergoing day-case angiograms represent a relatively high-risk population, yet often lack comprehensive risk-factor evaluation. Interventions have been shown to be more consistently aligned with guideline-recommended targets when conducted in hospital. As such, the cardiac catheterisation lab offers an invaluable opportunity for cardiovascular risk factor screening and intervention.
We enrolled 585 consecutive patients attending our institution for day-case coronary angiograms. Blood samples were collected for lipid profile and glycated haemoglobin (HbA1c), in addition to blood pressure recordings and a smoking history taken. The results were available for clinician review on the day, with encouragement to intervene on off-target risk factors.
We identified high levels of patients with established CAD and risk factors outside of the target range. This included 77% and 70% with low-density lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) above target, respectively. There were also 19% smoking and 14% with HbA1c above target. A number of patients with CAD and previously undiagnosed risk factors were also identified, including 18 newly diagnosed with diabetes. A considerable proportion of these had interventions made on the day of their procedure.
Our results demonstrate a clear benefit to risk-factor screening in the catheterisation lab, with a high number of patients found to have risk factors outside of the target range, or previously undiagnosed, and appropriate interventions were made as a result.
September 2026 Br J Cardiol 2026;33:119 doi :10.5837/bjc.2026.044
Mohamed Kira, Mohamed Abouelasaad, Ahmed Elshafey, Mohamed Darwish, Roopa Jairaj Patil, Zaynah Zubair, Alison Calver, Simon Corbett, Richard Jabbour, Michael Mahmoudi, John Rawlins, Rohit Sirohi, James Wilkinson, Jonathan Hinton, Nick Curzen
Unfractionated heparin (UFH) is routinely used in percutaneous coronary intervention (PCI). The aim of this study was to determine whether the required dose of heparin used during PCI procedures has increased over time, which was our subjective observation.
This retrospective study analysed the required heparin dosage in 100 consecutive patients undergoing isolated PCI for each year between 2016 and 2024, starting from 1 January of each year. The primary analysis compared the total heparin dose administered (a) unadjusted and (b) adjusted for weight and procedure duration, between annual populations. A secondary analysis compared heparin dosage in patients with at least one activated clotting time (ACT) value >250 seconds, the target ACT level at our centre.
The median total heparin dose rose from 9,000 units (U) in 2016 (interquartile range [IQR] 7,000–11,000 U), to 12,000 U (IQR 10,000–15,000 U) in 2024 (p<0.001). The median weight- and time-adjusted total heparin dose in 2016 was 1.95 (IQR 1.44–2.77) U/kg/min compared with 2.93 (IQR 2.1–3.8) U/kg/min in 2024 (p<0.001).
In the secondary analysis (in those who achieved a target ACT >250 seconds), the median dose was 1.81 (IQR 1.21–2.24) U/kg/min in 2016 versus 2.59 (IQR 2.03–3.22) U/kg/min in 2024 (p<0.001).
In conclusion, there has been a significant and unexplained increase in the total administered heparin dose for PCI cases in this centre between 2016 and 2024.
September 2026 Br J Cardiol 2026;33:120 doi :10.5837/bjc.2026.045
Ryan I Sia*, Aditya Sharma*, Jaswinder Gill, Anoop Shetty, Conn Sugihara, Jonathan Behar, Mark O’Neill, Matthew Wright, Aldo Rinaldi, John Whitaker
The most common site of origin of idiopathic premature ventricular complexes (PVCs) is the right ventricular outflow tract (RVOT). This study reports a single-centre UK National Health Service (NHS)-based experience of catheter ablation (CA) for idiopathic PVCs.
We conducted a retrospective review of the electronic patient record, searching for all patients undergoing idiopathic PVC ablation at Guy’s and St Thomas’ NHS Foundation Trust (GSTT) between January 2016 and June 2023. There were 147 procedures performed in 118 patients: 21 patients underwent repeat ablations. There were 75% originating in the RVOT and 11% from the left ventricular outflow tract (LVOT). Acute suppression of PVCs was achieved in 121 procedures (82%). Following acutely successful ablations, PVC burden reduction was greater in RVOT (85% decrease) than LVOT PVCs (44% decrease) at follow-up (p=0.03). There were 12 patients with PVC-induced cardiomyopathy identified. Following successful ablation (n=9), left ventricular ejection fraction (LVEF) increased from 38% to 49%. Symptomatic improvement after ablation was reported by 80%, with 64% having complete symptomatic resolution. Patients experiencing complete symptom resolution had a 92% decrease in PVC burden, whereas patients with residual symptoms had a 76.2% decrease (p=0.03).
Procedural complications occurred in 10 procedures (6.8%): five were classified as major, including four pericardial effusions requiring pericardiocentesis, and one cardioversion for pulseless ventricular tachycardia.
In conclusion, CA is an effective and safe strategy for PVC suppression in idiopathic PVCs, and may result in a significant symptomatic improvement even without complete PVC suppression. Among those with PVC-induced cardiomyopathy, CA results in improved LVEF.
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits